CD30 Antilichaam

Recognizes a single chain glycoprotein of 105/120kDa, identified as CD30/Ki-1. CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. In Hodgkin s disease, CD30/Ki-1 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T and B cells. This mAb distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45) .

The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

P28908

Human

A Co cell line established from a patient with Hodgkin s disease of T-cell lineage was used as the immunogen for the CD30 antibody.

SPM121

IHC-P

Unpurified high titer supernatant

Bioreactor concentrate

This CD30 antibody is available for research use only.

Store the CD30 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide) .

Prediluted in 1X PBS, 0.1 mg/mL BSA (US sourced), 0.05% sodium azide; *For IHC use only*

Cell surface, cytoplasmic

IHC testing of formalin-fixed, paraffin-embedded human Hodgkin's lymphoma stained with CD30 antibody (clone SPM121) .